Revisiting B-cell targeted therapies in rheumatoid arthritis: from paradoxical biology to deep immune reset
Targeted B-cell depletion via the anti-CD20 monoclonal antibody rituximab fundamentally altered the therapeutic algorithm for rheumatoid arthritis (RA). Despite its clinical entrenchment, approximately 40% of patients exhibit primary or secondary non-r…